HMOs: America Today, Britain Tomorrow? Exit the white coat, enter the pinstriped suit TESSA RICHARDS American medicine is being transformed from a profession into a business, and concern has been expressed about the "conflict between medical ethics and money making goals."' Those with a commercial bent have also been concerned, but not in the same way. They have seen the restructuring of nearly 11% of America's gross national product as a marvellous opportunity for making money.
The restructuring process has seen a steady erosion of fee for service practice and the rapid development of alternative Francisco's underground. How conMost HMOs were started on vincing would "Ahh the NHS" sound? a not for profit basis, but the trend has been to shift to a for profit status, and several HMOs publicly trade stocks. Two years ago these were an investor's dream, and, although the bloom has apparently gone off the peach now, investors both in America and overseas are still attracted to HMOs, encouraged by broadsheets from their stockbrokers that suggest: "We find the real growth potential available to HMOs and HMO hybrids to be immense. . . we anticipate the years of sustained growth and the success of a variety of different approaches that was characteristic of the fast food industry during its rapid growth period."' Now this attitude, to pursue the fast food analogy, may stick in the gullet, but few doubt that "the era of financing health care to support the development and application of scientific principles and knowledge . . ." is over. Decisions are no longer being made by physicians, and ". . . businessmen are becoming the most important influence in the redesign of the health care system."' But some sections in society are losing out as pressure to contain the cost of medical care increases. Doctors difficult task maintaining profitability admist bourgeoning competition. They do this mainly by expanding to reach new markets and by mounting stricter and stricter internal controls.
Nowhere are these controls more evident than in hospital care, and the medical director of Maxicare, a successful for profit HMO with over 670 000 members and groups of physicians in 13 different states, explained how he keeps an eye on the inpatient care. (This would, of course, be impossible without computers, and Maxicare has as many computer terminals as it has employees which puts the number at over 1200.) "Ideal" bed occupancy rates were set and monitored on a monthly basis. For a working population the ideal figure was 315 days per 1000 people enrolled per month, for Medicare patients (65 years and over) it was 2000 days. If the bed occupancy rates for individual groups came back at more than the ideal figures investigations were made to find out why there was excessive use. If they came back at less, underuse was suspected. This was equally worrying, for cutting corners just to make a profit would damage its reputation, and maintaining high quality care was an essential part of Maxicare's strategy.
Another part of all HMOs' strategy is to keep a close eye on what services their competitors are offering and for how much. Pleasing the customer is all important, and as much probably hinges on access to care as on the quality of that care. Americans find it hard to conceive how we in Britain put up with our long waiting lists and interminable waits in casualty, GPs' surgeries, outpatient departments, and so on, and the lack of freedom to see the doctor of our choice. They are used to ready access to medical care, provided they can afford it, and HMOs are well aware of this. It explains why, among other things, HMOs are tending to build increasing numbers of small satellite clinics so that going to the health plan will entail no more effort than going to the supermarket. Convenience this approach will be taken up more widely, so that eventually providers will be paid a fixed fee to take care of a group of potential patients regardless of their individual diagnoses.") Long term custodial care is hardly covered at all, and it appears that Medicare pays only 2% of the nation's nursing home bill,'2 leaving the rest to the patients (and their families), very few of whom can afford to take out insurance cover for this form of care. The cost of long term care is such that of those who need it, two thirds face a rapid decline into poverty. At this point they become eligible for Medicaid, and this programme pays for about 54% of the total nursing home bill. But patients need to be really poor to be eligible for this programme, and it too has been subject to cutbacks.
Conclusion
Growth in membership of HMOs reached a record 25% in 1985, and most people expect that membership will continue to grow-at what rate and how far is not known. Some believe that as much as half of the population will be enrolled in an HMO by 1995 and that [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] large "super meds" such as Kaiser will dominate, although smaller efficient regional organisations will continue to flourish. The more reactionary maintain that HMOs will peak before too long, but even they admit that the fee for service sector will never be quite the same again. Pressure from the competing alternative delivery systems and the financial constraints imposed by government, insurance companies, and large employers will ensure greater regulation and more cost effective practice.
In a health care environment that has changed considerably in the past few years, and is still actively fermenting, HMOs have acted as catalysts for change by exposing the uneconomical and inefficient practice of the fee for service sector and showing that there is a viable, cost effective alternative. Observers in Europe, the Middle East, and some Third World countries have followed their development with interest, and some proponents of HMOs believe that these organisations have the potential for selected international application.
Far from being the socialist, even communist inspired organisations that the medical profession in America once regarded with such distrust, HMOs, especially for the profit corporations, have emerged as blatant examples of pure capitalism. This worries even the enthusiasts, who admit that their continued growth is having some adverse effects: contributing to the widening gap between those that can afford health insurance and the poor who can't; squeezing the academic, teaching, and research institutes; and damaging the medical infrastructure in the rural areas. These factors together with the challenges and dilemmas posed by advances in technology and an increasingly large population of elderly people are weighty problems facing America's health care planners.
But these problems are not unique to America. We face them in Britain too, and arguably from a much weaker position in that our resources for health care are less, and in the current climate, failing to keep pace with demand. No one I spoke to in America, however, thought that HMOs were the answer to Britain's problems. Indeed, most thought that Britain was the last place for an HMO revolution, which is most likely to succeed in a wealthy country where a fee for service system dominates.
For all its warts, the NHS has much to commend it, not least because it ensures some equity of care. Unfortunately, at present neither the money nor the morale seems to be there to improve the service and prevent dissatisfied better off consumers from turning to the growing and increasingly American owned private sector. To suggest that chronic underfunding is not the major problem for the NHS would be untrue, but it is not the only problem, and we might benefit from doing more than merely observing the changes in America. Adopting both at primary care level and in hospital practice, some of the management systems, tight internal controls, incentives to doctors to practise cost effective medicine, and respect for the comfort and convenience ofpatients-key factors behind the success of America's HMOs-might well benefit the NHS.
Meanwhile, it is salutary to remember that the discontent among a sizable proportion of America's doctors, who have seen their power and autonomy decline with such rapidity, is largely due to their reluctance to read the writing on the wall.
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A middle aged man developed a painful skin reaction-presumably allergic-to the use ofafirst aid sprayfor minor burns containing benzocaine. Is he likely to be allergic to other local anaesthetics?
Although the incidence of allergic reactions to topical anaesthetic agents is low, such reactions are well documented, and usually the reaction is to the active drug rather than to a preservative.' Benzocaine is an ester, and several patients have been shown to cross react with other local anaesthetic agents, especially those with an ester grouping.' 3Nevertheless, there appears to be little cross reactivity with amides. Thus a patient allergic to benzocaine should avoid drugs that contain benzocaine such as benzocaine (AAA throat spray, Intralgin. Nestosyl, Medilave gel), novobiocin sodium (Audicort), phenazone (Auralgicin, Auraltone), chlorhexidine gluconate solution (Hibitane), adrenaline acid tartrate (Rybarvin), methyl nicotinate (Transvasin), and tyrothricin (Tyrozets). Similar esters are to be found in Locan, which contains amethocaine and amylocaine, and procaine, but that is only used parentally. Amides such as lignocaine are probably safe. This anaesthetic is present in preparations such as Xyloton, which is used in dental anaesthetics and sprays, Locaine ointment 5%, used in surface anaesthesia, and Xyloproct, used for haemorrhoids.-w j CUNLIFFE, consultant dermatologist, Leeds.
I Cronin E. Contact dermatitis. Edinburgh: Churchill Livingstone, 1980:1%. Is it safe to start pertussis immunisation in a 3 year old girl with congenital optic nerve hypoplasia who is otherwise developing normally and in whom there is no family history ofepilepsy? Pertussis immunisation was omittedfrom the primary course ofimmunisations due to the uncertainty ofher develpment at that time.
Congenital optic nerve hypoplasia is often associated with neuroendocrine dysfunction and anterior midline cerebral defects, especially absent septum pellucidum. Even if clinically inapparent neurological defects are present this girl's condition is stable and pertussis immunisation is not contraindicated.'2 As this condition is not common a specific benefit risk ratio is not available, but I think that it would differ little from that of a normal child. Further consideration should be given to her age, the current incidence of pertussis, and the presence of younger family members. Most mortality and severe morbidity results from pertussis infection in the first year oflife, particularly the first six months. The severity ofthe disease tends to lessen with increasing age, but the younger child can still expect to suffer a prolonged illness with troublesome cough and vomiting. Pertussis vaccine, however, would not normally be offered over 6 years of age. At present notifications of pertussis are rising in Britain, and this probably represents the start ofthe next of the three to four yearly epidemics, the last ones having been in 1977-9 and 1981-3. Pertussis vaccine acceptance rates are slowly rising from a low of 30% in 1978 but were still only 65% in England and Wales for 1984. The outbreak is therefore likely to be sizeable though slightly smaller than the last two. An older child often brings pertussis into the house and may then infect younger siblings, these being more at risk and who also may not yet be old enough to have received a full primary course of immunisation, if any. I would recommend pertussis immunisation for this girl as infection is likely during the coming epidemic. This would also help protect any younger siblings. As her other routine immunisations have been given, monovalent pertussis vaccine should be used with two boosters at monthly intervals thereafter.-GLYN R WILLIAMS, lecturer in infectious diseases, Glasgow. Is there any justification for using a combination of steroids and antibiotics in a short course in the hope of reducing some of the discomfort and complications of herpes zoster, in particular when it affects the first division of the fifth cranial nerve? Can carbamazepine be usedprophylactically in the same way toprevent the full horrors ofpostherpetic neuralgia? Ifso what would be an appropriate dose?
Steroids reduce the incidence of postherpetic neuralgia'; in one study of patients over the age of 50,265% ofthe control group developed postherpetic neuralgia lasting up to two years, whereas only 15% of the group treated with steroids suffered this complication, and in no case did it persist longer than six months.2 The steroid regimen used was 40 mg prednisolone daily for 10 days, with gradual reduction over the next three weeks. Patients with contraindications to steroids were excluded from the trial, and complications of treatment were not observed. Skin healing was appreciably quicker in the group treated with steroids. There is no justification for using prophylactic antibiotics in zoster; they should be reserved for secondary bacterial infection. Acyclovir eye ointnent is effective, however, and should be given to all patients with affected eyes; they should also see an ophthalmologist.
Systemic acyclovir (10 mg/kg thrice daily, reduced in renal failure) should be reserved for patients who have impaired cell mediated immunity or who have particularly severe zoster that is still spreading. Carbamazepine is ineffective in preventing postherpetic neuralgia and was used in the control group of the above study as a placebo, with the results described.-j E BANATvALA, professor of clinical virology, London. 
